Cue Biopharma Inc (CUE)

0.28 +0.50%

Cue Biopharma Inc (CUE) is currently trading at $0.28. This represents a gain of 0.5% from the previous session. With a market capitalization of $0.02B, CUE is a key component of the Health Care sector. Investors looking to trade CUE should compare margin rates and options platforms to optimize their portfolio management.

Broker Promotion
Get 15 Free Stocks on Moomoo → T&Cs Apply. Trade CUE commission-free.
Trading Platform Comparison
Moomoo
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Good for small traders
IBKR
  • Min Deposit: $0
  • Commissions: $0–$0.005/share
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Professional-level tools
Ameritrade
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Strong research tools
Webull
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Easy mobile app
AI Market Sentiment

As of today, Cue Biopharma Inc (CUE) shows a bullish trend. Analysts are watching the 0.30 level closely.

Fundamentals
Mkt Cap0.02B
P/E Ratio0.0000
Volume338,327
Others Watching (By Market Cap)
INKT
Mink Therapeuti $11.50
+0.23% CLNN
Clene Inc $5.02
-1.39% NTRB
Nutriband Inc $4.46
+0.90% ACRV
Acrivon Therape $1.62
+9.00% ESLA
Estrella Immuno $1.21
+1.68%
60-Day Technical Chart
Advanced Charting

Need more indicators for CUE? Use the world's #1 platform.

Open CUE on TradingView →
Charting Platforms
TradingView

Advanced charts & indicators, web & mobile

StockCharts

Technical analysis charts with overlays & indicators

BarCharts

Market data, charts, and technical signals

Finviz

Visual stock charts & heatmaps

Yahoo Finance Charts

Basic interactive charts with indicators

Side-by-Side: Stocks Near $0
Metric CUE
+0.50% 		NAKA
+14.39% 		NOTV
-0.04% 		TVGN
+2.88%
Price $0.28 $0.26 $0.27 $0.29
Mkt Cap $0.02B $0.11B $0.01B $0.06B
- View → View → View →
Latest Headlines
AVOZ Altavoz Entertainment (PNK) volume 44,100 on 25 Feb 2026: liquidity cue Meyka • Feb 25, 2026 Autoimmune drug candidate CUE-401 passes early safety tests in animals Stock Titan • Feb 17, 2026 CUE-101 Plus Pembrolizumab Yields 50% ORR in HPV+ HNSCC With Low PD-L1 Expression OncLive • Jul 16, 2025 Cue Biopharma stock adds to gains after Nobel Prize validates CUE-401 approach Investing.com • Oct 9, 2025 Insider Makes Bold Move With Fresh Cue Biopharma Stock Purchase TipRanks • Jan 2, 2026
● Gemini Agentic AI Analyst Insight for CUE
Market Education
View All Articles →
External Research